» Articles » PMID: 26681974

Guidelines for Cytopathologic Diagnosis of Epithelioid and Mixed Type Malignant Mesothelioma. Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou...

Abstract

To provide practical guidelines for the cytopathologic diagnosis of malignant mesothelioma (MM). Cytopathologists involved in the International Mesothelioma Interest Group (IMIG) and the International Academy of Cytology (IAC), who have an interest in the field contributed to this update. Reference material includes peer-reviewed publications and textbooks. This article is the result of discussions during and after the IMIG 2012 conference in Boston, followed by thorough discussions during the 2013 IAC meeting in Paris. Additional contributions have been obtained from cytopathologists and scientists, who could not attend these meetings, with final discussions and input during the IMIG 2014 conference in cape town. During the previous IMIG biennial meetings, thorough discussions have resulted in published guidelines for the pathologic diagnosis of MM. However, previous recommendations have stated that the diagnosis of MM should be based on histological material only.[12] Accumulating evidence now indicates that the cytological diagnosis of MM supported by ancillary techniques is as reliable as that based on histopathology, although the sensitivity with cytology may be somewhat lower.[345] Recognizing that noninvasive diagnostic modalities benefit both the patient and the health system, future recommendations should include cytology as an accepted method for the diagnosis of this malignancy.[67] The article describes the consensus of opinions of the authors on how cytology together with ancillary testing can be used to establish a reliable diagnosis of MM.

Citing Articles

Telomeres and telomerase in mesothelioma: Pathophysiology, biomarkers and emerging therapeutic strategies (Review).

Andreikos D, Spandidos D, Georgakopoulou V Int J Oncol. 2025; 66(3).

PMID: 39981889 PMC: 11844339. DOI: 10.3892/ijo.2025.5729.


Role of Ancillary Techniques in Reporting Serous Fluid Cytology - "Redefining Categories, Refining Diagnosis".

Kapoor S, Samanta S, Kaur K J Cytol. 2024; 41(2):96-104.

PMID: 38779601 PMC: 11108034. DOI: 10.4103/joc.joc_114_23.


Validation of a Gene Expression Approach for the Cytological Diagnosis of Epithelioid and Biphasic Pleural Mesothelioma on a Consecutive Series.

Bruno R, Poma A, Ali G, Proietti A, Ribechini A, Chella A Cancers (Basel). 2023; 15(23).

PMID: 38067238 PMC: 10705177. DOI: 10.3390/cancers15235534.


Cytology of malignant pleural mesothelioma: Diagnostic criteria, WHO classification updates, and immunohistochemical staining markers diagnostic value.

Shaker N, Wu D, Abid A Diagn Cytopathol. 2022; 50(11):532-537.

PMID: 36069384 PMC: 9826471. DOI: 10.1002/dc.25053.


The Use of Immunohistochemistry, Fluorescence Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review.

Rozitis E, Johnson B, Cheng Y, Lee K Front Oncol. 2020; 10:1742.

PMID: 33014860 PMC: 7509088. DOI: 10.3389/fonc.2020.01742.


References
1.
Pass H, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M . Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 2007; 85(1):265-72. DOI: 10.1016/j.athoracsur.2007.07.042. View

2.
Dejmek A, Hjerpe A . Carcinoembryonic antigen-like reactivity in malignant mesothelioma. A comparison between different commercially available antibodies. Cancer. 1994; 73(2):464-9. DOI: 10.1002/1097-0142(19940115)73:2<464::aid-cncr2820730235>3.0.co;2-#. View

3.
Bovin N, Obukhova P, Shilova N, Rapoport E, Popova I, Navakouski M . Repertoire of human natural anti-glycan immunoglobulins. Do we have auto-antibodies?. Biochim Biophys Acta. 2012; 1820(9):1373-82. DOI: 10.1016/j.bbagen.2012.02.005. View

4.
Matsumoto S, Nabeshima K, Kamei T, Hiroshima K, Kawahara K, Hata S . Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology. Cancer Cytopathol. 2013; 121(8):415-22. DOI: 10.1002/cncy.21269. View

5.
Pinelli V, Laroumagne S, Sakr L, Marchetti G, Tassi G, Astoul P . Pleural fluid cytological yield and visceral pleural invasion in patients with epithelioid malignant pleural mesothelioma. J Thorac Oncol. 2012; 7(3):595-8. DOI: 10.1097/JTO.0b013e31823e0667. View